Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Soluble TIM-3, likely produced by myeloid cells, predicts resistance to immune checkpoint inhibitors in metastatic clear cell renal cell carcinoma

Fig. 5

Obradovic et al. ccRCC scRNAseq dataset. A Tumor and adjacent tissue samples. Upper section: UMAP of cell lineages; middle section: HAVCR2 expression; lower section: HAVCR2 + ADAM + double-positive cells repartition. B % of cells in the pooled dataset expressing HAVCR2 and ADAM10 and/or ADAM17 in broad lineages. HAVCR2 + ADAM10 +—detection of ADAM10 transcripts but not ADAM17; HAVCR2 + ADAM17 +—detection of ADAM17 transcripts but not ADAM10, HAVCR2 + ADAM10 + 17 +—detection of both metalloproteinases. C Comparison of the proportions of HAVCR2 + ADAM + cells within the lymphoid and myeloid lineages, for each patient in tumor samples

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us